Cargando…

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview

Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez, Sandra, Muñoz, Andrés, Bustos, Rosa-Helena, Jaimes, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555940/ https://www.ncbi.nlm.nih.gov/pubmed/32842558 http://dx.doi.org/10.3390/biomedicines8090303

Ejemplares similares

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

Pharmacovigilance in Italy: An overview
por: Mazzitello, Carmela, et al.
Publicado: (2013)

Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview
por: Avila, Maria-Paula, et al.
Publicado: (2020)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data
por: Bellavite, Paolo, et al.
Publicado: (2021)

Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013)

Role of Pharmacovigilance in India: An overview
por: Suke, Sanvidhan G, et al.
Publicado: (2015)

An historical overview over Pharmacovigilance
por: Fornasier, Giulia, et al.
Publicado: (2018)

Pharmacovigilance in the Caribbean Countries: an Overview
por: Walker, Kingsley E.W., et al.
Publicado: (2023)

Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting
por: Hadi, Muhammad Abdul, et al.
Publicado: (2017)

Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
por: Scicchitano, Francesca, et al.
Publicado: (2012)

Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
por: Giofrè, Chiara, et al.
Publicado: (2013)

Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
por: Schmider, Juergen, et al.
Publicado: (2018)

Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
por: Castro, Leonor S., et al.
Publicado: (2021)

An Overview on Dietary Polyphenols and Their Biopharmaceutical Classification System (BCS)
por: Truzzi, Francesca, et al.
Publicado: (2021)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
por: Shrestha, Sunil, et al.
Publicado: (2021)

Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals
por: Reijers, Joannes A. A., et al.
Publicado: (2019)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022)

Biopharmaceutical insights of particulate emulsified systems - a prospective overview
por: Katamreddy, Jyothshna Devi, et al.
Publicado: (2018)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance
por: Vilar, Santiago, et al.
Publicado: (2015)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

Pharmacovigilance: Basic concepts and an overview of the system in Oman
por: Jose, Jimmy, et al.
Publicado: (2021)

Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
por: Palleria, Caterina, et al.
Publicado: (2018)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital
por: Vural, Fisun, et al.
Publicado: (2015)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India
por: Prakash, Jai, et al.
Publicado: (2021)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_19m4du6thdulb3d13t3r4pjmce